Enfermedad del hígado graso no alcohólico, asociación con la enfermedad cardiovascular y tratamiento (II). Tratamiento de la enfermedad del hígado graso no alcohólico
- Brea, Ángel
- Pintó, Xavier
- Ascaso, Juan F.
- Blasco, Mariano
- Díaz, Ángel
- González-Santos, Pedro
- Hernández-Mijares, Antonio
- Mantilla, Teresa
- Millán, Jesús
- Pedro-Botet, Juan
ISSN: 0214-9168, 1578-1879
Ano de publicación: 2017
Volume: 29
Número: 4
Páxinas: 185-200
Tipo: Artigo
Outras publicacións en: Clínica e investigación en arteriosclerosis
Resumo
Disease nonalcoholic fatty liver disease (NAFLD) comprises a series of histologically similar to those induced by alcohol consumption in people with very little or no liver damage same. The importance of NAFLD is its high prevalence in our Western societies, from the point of view liver in its progressive evolution from steatosis to steatohepatitis, cirrhosis and liver cancer. During the last decade it has been observed that NAFLD leads to an increased cardiovascular risk with accelerated atherosclerosis and cardiovascular events, the leading cause of morbidity and mortality. This updated January 2016 revision consists of two parts. In this second part, the treatment of NAFLD and its influence on cardiovascular disease and drugs used in the control of cardiovascular risk factors showing a beneficial effect on the liver disease will be reviewed.